Ginkgo Bioworks (DNA)
(Delayed Data from NYSE)
$8.27 USD
+0.48 (6.16%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $8.27 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$8.27 USD
+0.48 (6.16%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $8.27 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
Zacks News
Ginkgo Bioworks Holdings, Inc. (DNA) Stock Slides as Market Rises: Facts to Know Before You Trade
by Zacks Equity Research
Ginkgo Bioworks Holdings, Inc. (DNA) closed the most recent trading day at $7.70, moving -0.77% from the previous trading session.
Curis (CRIS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Curis (CRIS) delivered earnings and revenue surprises of -19.41% and 15.73%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Ginkgo Bioworks Holdings, Inc. (DNA) Advances While Market Declines: Some Information for Investors
by Zacks Equity Research
Ginkgo Bioworks Holdings, Inc. (DNA) concluded the recent trading session at $0.37, signifying a +0.3% move from its prior day's close.
Ginkgo (DNA) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Ginkgo's (DNA) total revenues are likely to have declined in the second quarter, owing to the expected ramp-down of the company's K-12 COVID testing services.
Why the Market Dipped But Ginkgo Bioworks Holdings, Inc. (DNA) Gained Today
by Zacks Equity Research
The latest trading day saw Ginkgo Bioworks Holdings, Inc. (DNA) settling at $0.30, representing a +0.6% change from its previous close.
Ginkgo Bioworks Holdings, Inc. (DNA) Sees a More Significant Dip Than Broader Market: Some Facts to Know
by Zacks Equity Research
The latest trading day saw Ginkgo Bioworks Holdings, Inc. (DNA) settling at $0.32, representing a -1.51% change from its previous close.
After Plunging -40.22% in 4 Weeks, Here's Why the Trend Might Reverse for Ginkgo Bioworks (DNA)
by Zacks Equity Research
Ginkgo Bioworks (DNA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Ginkgo Bioworks (DNA) delivered earnings and revenue surprises of 0% and 16.60%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Ginkgo Bioworks Holdings, Inc. (DNA) delivered earnings and revenue surprises of 0% and 20.81%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Ginkgo (DNA) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Ginkgo's (DNA) fourth-quarter earnings call, investor focus is likely to be on the sales performance of its two business units, Biosecurity and Cell Engineering.
Insmed (INSM) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Insmed (INSM) delivered earnings and revenue surprises of -13.27% and 0.15%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Ginkgo (DNA) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
On Ginkgo's (DNA) third-quarter earnings call, investor focus is likely to be on the sales performance of its two business units ¿¿¿ Biosecurity and Cell Engineering.
Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ginkgo Bioworks Holdings, Inc. (DNA) delivered earnings and revenue surprises of 0% and 14.43%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ginkgo Bioworks Holdings, Inc. (DNA) delivered earnings and revenue surprises of 11.11% and 30.07%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Anika Therapeutics (ANIK) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Anika (ANIK) delivered earnings and revenue surprises of -97.22% and 2.05%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Ligand Pharmaceuticals (LGND) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Ligand (LGND) delivered earnings and revenue surprises of 121.36% and 12.13%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ginkgo Bioworks Holdings, Inc. (DNA) delivered earnings and revenue surprises of 86.67% and 16.44%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ginkgo Bioworks Holdings, Inc. (DNA) delivered earnings and revenue surprises of -60% and 22.33%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Poseida Therapeutics, Inc. (PSTX) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Poseida Therapeutics, Inc. (PSTX) delivered earnings and revenue surprises of 235.29% and 5,715.30%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Tarsus Pharmaceuticals, Inc. (TARS) delivered earnings and revenue surprises of 14.29% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
2seventy bio, Inc. (TSVT) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
2seventy bio, Inc. (TSVT) delivered earnings and revenue surprises of -1.15% and 25.71%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Ginkgo (DNA) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
On Ginkgo's (DNA) third-quarter earnings call, investor focus is likely to be on the company's progress with its collaboration deals and the performance of its business units.
IGM Biosciences, Inc. (IGMS) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
IGM Biosciences, Inc. (IGMS) delivered earnings and revenue surprises of 8.97% and 15.13%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Ginkgo Bioworks Holdings, Inc. (DNA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Ginkgo Bioworks Holdings, Inc. (DNA) closed at $2.74 in the latest trading session, marking a +0.37% move from the prior day.
Ginkgo Bioworks Holdings, Inc. (DNA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Ginkgo Bioworks Holdings, Inc. (DNA) closed at $2.78, marking a +0.72% move from the previous day.